<DOC>
	<DOCNO>NCT01352884</DOCNO>
	<brief_summary>This Phase 1 , open-label , multi-center , first time human study AMP-224 adult patient cancer respond standard therapy . This study conduct two stage consist Dose-Escalation stage Expansion Stage .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetics AMP-224 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Must able provide inform consent In DoseEscalation : Must solid tumor malignancy cutaneous Tcell lymphoma relapse refractory standard therapy , standard therapy exist In Expansion Phase : Must melanoma ovarian cancer histologically cytologically confirm Ovarian cancer patient must recurrent persistent nonmucinous disease , must receive 2 prior chemotherapeutic regimen Melanoma patient must recurrent persistent nonocular AJCC Stage IIIC IV disease surgically incurable unresectable Melanoma patient document BRAF mutation know responsive BRAF inhibitor must fail intolerant inhibitor Must measurable disease Must able provide access archival ( DoseEscalation Phase ) and/or fresh tumor tissue ( DoseEscalation Expansion Phases ) Screening prior study entry Must least 18 year old Must adequate organ function Prior cancer therapy must complete least 14 day 5 halflives ( whichever longer ) prior first dose AMP224 Prior treatment antiPD1 antibody therapy Known antibody response prior antibody therapy fusion protein therapeutic Major surgery within 4 week prior first dose AMP224 Prior allogeneic autologous bone marrow organ transplantation Known and/or history evidence autoimmune disease except vitiligo , resolve childhood asthma stable hypothyroidism Received immunomodulatory drug within 2 week first dose AMP224 Active infection require antibiotic , physician monitoring , recurrent fever &gt; 100.4 degree fahrenheit associate clinical diagnosis active infection Patients cirrhosis Clinically significant cardiac electrocardiogram abnormality History evidence HIV Active viral disease ( except viral infection associate malignancy ) Regular use illicit drug recent history substance abuse Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Tumor</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Melanoma</keyword>
</DOC>